Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 12,475 matching trials from the live ClinicalTrials.gov search.
Conditions
Carcinoma, Renal Cell, Carcinoma, Urothelial
Interventions
Immune cell and CTC detection procedures
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Pancreatitis, Chronic; Diabetes; Transplant
Interventions
etanercept, Alpha 1-Antitrypsin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Non-melanomatous Skin Cancer
Interventions
Polyphenon E and Placebo
Drug
Lead sponsor
Frank Meyskens
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Orange, California
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions
PLX-PAD
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
40 Years to 81 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Birmingham, Alabama • Durham, North Carolina
Conditions
Prostatic Neoplasms
Interventions
JNJ-78278343, JNJ-95298177, JNJ-87189401
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Sarasota, Florida • New York, New York • Cleveland, Ohio + 1 more
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
therapeutic conventional surgery, sorafenib tosylate, laboratory biomarker analysis
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Relapsed, Refractory Multiple Myeloma
Interventions
RAPA-201 Autologous T cells
Biological
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Mantle Cell Lymphoma, Lymphoma, Mantle Cell
Interventions
EPOCH-R, GM-CSF, Idiotype vaccine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hemophilia A
Interventions
Nuwiq
Drug
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
combination nivolumab and ipilimumab
Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell Tumors
Interventions
Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma, Myeloma
Interventions
Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY), Tacrolimus, Mycophenolate Mofetil (MMF), Hematopoietic Stem Cell Transplant (HSCT)
Radiation · Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Lung Cancer
Interventions
antitumor drug screening assay
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients

NCT04678440
Conditions
Lung Cancer, Nonsmall Cell
Interventions
[18F]F-AraG Imaging
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Conditions
Non-Small Cell Lung Cancer
Interventions
enzastaurin, pemetrexed, docetaxel, carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina • Columbia, South Carolina + 1 more
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
NRTX-1001, Sham Comparator
Biological · Procedure
Lead sponsor
Neurona Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2043
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
Terminated Early Phase 1 Interventional Results available

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

NCT02774291
Conditions
HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Aldesleukin, Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes, Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 66 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lumiliximab + FCR, FCR
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Gainesville, Florida • Miami, Florida • Chicago, Illinois + 5 more
Conditions
Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
imatinib mesylate, paclitaxel
Drug
Lead sponsor
University of Washington
Other
Eligibility
70 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Albuquerque, New Mexico • Seattle, Washington
Conditions
Ototoxicity, Drug-Induced
Interventions
Sodium Thiosulfate
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 39 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Brain and Central Nervous System Tumors
Interventions
fluorescence in situ hybridization, loss of heterozygosity analysis, polymerase chain reaction, flow cytometry, immunohistochemistry staining method
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2013
U.S. locations
38
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Clive, Iowa + 19 more
Conditions
Anemia, Sickle Cell
Interventions
ICL670, deferoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
34
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Conditions
Obesity and Obesity-related Medical Conditions
Interventions
Bariatric Surgery, Semaglutide, Tirzepatide
Procedure · Drug
Lead sponsor
Ali Aminian
Other
Eligibility
18 Years to 70 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Exercise, Transplantation
Interventions
Exercise program
Other
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
4 Years to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona